PetVivo Holdings, Inc. (PETV)
USD 0.63
(4.99%)
USD 0.63
(4.99%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -10.49 Million USD | -21.76% |
| 2023 | -8.61 Million USD | -73.87% |
| 2022 | -4.99 Million USD | -168.29% |
| 2021 | -1.87 Million USD | -31.36% |
| 2020 | -1.49 Million USD | 63.66% |
| 2019 | -3.92 Million USD | -138.87% |
| 2018 | -1.64 Million USD | 89.5% |
| 2017 | -16.38 Million USD | -523.83% |
| 2016 | -2.5 Million USD | -108.64% |
| 2015 | -1.2 Million USD | -6006.38% |
| 2014 | -19.68 Thousand USD | 74.96% |
| 2013 | -78.59 Thousand USD | 23.08% |
| 2012 | -102.17 Thousand USD | 61.02% |
| 2011 | -262.12 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 FY | - USD | -11.98% |
| 2024 Q1 | -2.86 Million USD | -24.11% |
| 2024 Q2 | -2.91 Million USD | -26.69% |
| 2024 Q4 | -2.28 Million USD | -83.17% |
| 2024 Q3 | -1.71 Million USD | 52.64% |
| 2023 Q4 | -2.3 Million USD | -0.91% |
| 2023 Q3 | -2.28 Million USD | -9.43% |
| 2023 Q2 | -2.08 Million USD | -7.74% |
| 2023 Q1 | -1.93 Million USD | -10.46% |
| 2023 FY | - USD | -73.87% |
| 2022 Q2 | -1.08 Million USD | -115.73% |
| 2022 FY | - USD | -168.29% |
| 2022 Q1 | -504.92 Thousand USD | -56.2% |
| 2022 Q3 | -1.64 Million USD | -50.76% |
| 2022 Q4 | -1.75 Million USD | -6.87% |
| 2021 Q2 | -797.73 Thousand USD | -106.32% |
| 2021 Q1 | -386.65 Thousand USD | -1.72% |
| 2021 FY | - USD | -31.36% |
| 2021 Q3 | -364.63 Thousand USD | 54.29% |
| 2021 Q4 | -323.24 Thousand USD | 11.35% |
| 2020 FY | - USD | 63.66% |
| 2020 Q1 | -349.63 Thousand USD | 65.83% |
| 2020 Q2 | -288.57 Thousand USD | 17.46% |
| 2020 Q3 | -406.99 Thousand USD | -41.04% |
| 2020 Q4 | -380.11 Thousand USD | 6.61% |
| 2019 Q1 | -1.93 Million USD | -143.23% |
| 2019 Q4 | -1.02 Million USD | -157.7% |
| 2019 Q3 | -397.02 Thousand USD | 29.85% |
| 2019 Q2 | -565.97 Thousand USD | 70.77% |
| 2019 FY | - USD | -138.87% |
| 2018 FY | - USD | 89.5% |
| 2018 Q4 | -795.93 Thousand USD | -113.3% |
| 2018 Q3 | -373.15 Thousand USD | -145.76% |
| 2018 Q1 | -321 Thousand USD | 37.46% |
| 2018 Q2 | -151.84 Thousand USD | 52.7% |
| 2017 FY | - USD | -523.83% |
| 2017 Q1 | -428.4 Thousand USD | 59.61% |
| 2017 Q4 | -513.3 Thousand USD | -53.43% |
| 2017 Q3 | -334.55 Thousand USD | 97.7% |
| 2017 Q2 | -14.51 Million USD | -3288.88% |
| 2016 Q1 | -985.47 Thousand USD | -480.83% |
| 2016 FY | - USD | -108.64% |
| 2016 Q4 | -1.06 Million USD | -256.23% |
| 2016 Q3 | -297.73 Thousand USD | -81.82% |
| 2016 Q2 | -163.75 Thousand USD | 83.38% |
| 2015 Q2 | -105.83 Thousand USD | 88.49% |
| 2015 Q1 | -919.52 Thousand USD | -213.34% |
| 2015 FY | - USD | -6006.38% |
| 2015 Q3 | -200.81 Thousand USD | -89.74% |
| 2015 Q4 | -169.66 Thousand USD | 15.51% |
| 2014 Q4 | 811.26 Thousand USD | 630.13% |
| 2014 Q3 | -153.03 Thousand USD | 82.76% |
| 2014 Q2 | -887.74 Thousand USD | -4787.13% |
| 2014 FY | - USD | 74.96% |
| 2014 Q1 | -18.16 Thousand USD | -18.27% |
| 2013 Q1 | -22.73 Thousand USD | 48.26% |
| 2013 Q2 | -19.96 Thousand USD | 12.18% |
| 2013 Q3 | -20.54 Thousand USD | -2.91% |
| 2013 Q4 | -15.35 Thousand USD | 25.23% |
| 2013 FY | - USD | 23.08% |
| 2012 Q3 | -23.71 Thousand USD | -74.49% |
| 2012 Q2 | -13.59 Thousand USD | 35.13% |
| 2012 Q1 | -20.94 Thousand USD | -55.27% |
| 2012 FY | - USD | 61.02% |
| 2012 Q4 | -43.93 Thousand USD | -85.26% |
| 2011 FY | - USD | 0.0% |
| 2011 Q1 | -170 Thousand USD | 0.0% |
| 2011 Q2 | -40.73 Thousand USD | 76.04% |
| 2011 Q3 | -35.95 Thousand USD | 11.73% |
| 2011 Q4 | -13.49 Thousand USD | 62.47% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acutus Medical, Inc. | -13.48 Million USD | 22.188% |
| Biotricity, Inc. | -8.82 Million USD | -18.874% |
| Cell MedX Corp. | - USD | Infinity% |
| Dynatronics Corporation | -976 Thousand USD | -975.246% |
| Nemaura Medical Inc. | -7.28 Million USD | -44.015% |
| RetinalGenix Technologies Inc. | -2.08 Million USD | -402.863% |
| Sonendo, Inc. | -54.76 Million USD | 80.838% |
| Telesis Bio, Inc. | -40.49 Million USD | 74.083% |
| Talis Biomedical Corporation | -66.04 Million USD | 84.11% |
| Viveve Medical, Inc. | -20.61 Million USD | 49.098% |